Dose Modifications of Ribociclib and Endocrine Therapy for Treatment of ER+ HER2- metastatic Breast Cancer

Kristoffer Bøss Kristensen (kristoffer.kristensen@gmail.com)
Aarhus University Hospital: Aarhus Universitetshospital https://orcid.org/0000-0003-4738-0189
Ida Marie Nedergaard Thomsen
Copenhagen University Hospital: Rigshospitalet
Tobias Berg
Copenhagen University Hospital: Rigshospitalet
Annette R. Kodahl
Odense University Hospital: Odense Universitetshospital
Anders B. Jensen
Aarhus University Hospital: Aarhus Universitetshospital

Research Article

Keywords: Metastatic breast cancer, ribociclib, CDK 4/6 inhibitor, dose reduction, dose modifications, progression free survival

Posted Date: February 10th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-215362/v1

Version of Record: A version of this preprint was published at Breast Cancer Research and Treatment on April 10th, 2021. See the published version at https://doi.org/10.1007/s10549-021-06215-6.

Abstract

Purpose: Treatment for estrogen receptor positive (ER+), human epidermal receptor 2 negative (HER2-) metastatic breast cancer (MBC) has improved with the approval of CDK 4/6 inhibitors. Clinical trials with the CDK4/6 inhibitor ribociclib, suggest that between 35% to 57.5% of the patients experience a dose reduction during treatment. Information on the possible consequences of dose reduction concerning efficacy is needed. ***Methods:*** A retrospective cohort study on patients with ER+ HER2- MBC from three Danish oncology departments. Data on tolerability and progression-free survival were collected from electronic health records. ***Results:*** 128 patients with ER+ HER2- MBC who initiated ribociclib treatment between 1st January 2018 to 31st March 2020 were included in our analysis. Of these patients, 48.4% required one or more dose reductions. Overall median PFS was 19.2 months (CI-95%: 14.3-NR). Patients with one or more dose reductions did not have decreased median PFS (19.2 months, CI-95%: 14.3-NR compared to 12.2 months, CI-95%: 7.3-NR. p=0.078). Frequency of adverse events were as previously reported, with grade III and IV neutropenia occurring in 45.3% and 7% of patients, respectively. Patients treated with fulvestrant versus an aromatase inhibitor and patients with lymph node involvement at baseline had lower odds of requiring dose reduction (OR_a = 0.30, CI-95%: 0.18-0.89 & OR_a = 0.41, CI-95%: 0.12-0.73, respectively). ***Conclusion***: Our results indicate that dose reduction of ribociclib is safe and do not compromise the efficacy of the treatment. Furthermore, the study supports translation of results from the MONALEESA trials to patients treated in real-world clinical settings.

Introduction

Breast cancer remains the leading cause of cancer-related death for women worldwide. Global cancer statistics estimate approximately 2 million new cases each year[1]. Although a marked improved prognosis over the last decades, up to 20% of breast cancer patients still develop recurrent disease[2]. Patients diagnosed with metastatic breast cancer (MBC) have a median survival time of 4–5 years [3]. For MBC, treatment is mainly determined by molecular subtype based on presence or absence of human epidermal growth receptor 2 (HER2) and estrogen receptor (ER). In 70% of breast cancer cases, the tumor is ER + and HER2-[4]. As first-line treatment for ER + HER2- MBC, international treatment guidelines recommend the combination of endocrine therapy and targeting agents as CDK4/6 inhibitors [5].

CDK 4/6 proteins are important in regulating cell growth. CDK 4/6 forms complex with D-type cyclins. The formed complex phosphorylates Rb1. Hypophosphorylated Rb1 represses the E2F transcription factors which transcript genes required for shifting cell from G1 to S-phase. When Rb1 is phosphorylated it no longer represses E2F, and thus the CDK 4/6 cyclin complex effectively promotes cell cycle. By preventing formation of the CDK 4/6 cyclin complex, CDK 4/6 inhibitors can therefore inhibits cell cycle progression [6]. The CDK4/6-Rb1-E2F signaling complex is frequently found dysregulated in cancer contributing to tumorigenesis [7]. Given this key role in cell growth and a link to tumorigenesis, research has long proposed CDK 4/6 as a target in anti-neoplastic therapy for MBC[8].

Currently, three CDK 4/6 inhibitors are approved for clinical use, namely palbociclib, abemaciclib and ribociclib. Palbociclib was approved first based on results from the PALOMA-trials[9, 10]. Retrospective studies further support these results[11, 12]. Abemaciclib is the most recently approved CDK 4/6 inhibitor. It was granted approval following the MONARCH-trials[13]. Due to the recent approval, real-world data on safety and efficacy is sparse[14]. Ribociclib was initially approved in 2017 (EMA) based on results from MONALEESA-2. Ribociclib improved progression free survival (PFS) in postmenopausal woman when combined with either an aromatase inhibitor (AI) (MONALEESA-2)[15] or fulvestrant (MONALEESA-3)[16], as well as with tamoxifen or an AI in premenopausal women (MONALEESA-7)[17]. Additionally, while data on overall survival in MONALEESA-2 remains immature, overall survival is significantly improved in both MONALEESA 3 & 7[18, 19].

Data on tolerability from the MONALEESA trials suggest, that ribociclib and endocrine treatment is generally well tolerated[16, 17, 20]. Neutropenia is the most common cause of grade III or IV adverse events. Other frequently reported adverse events include nausea, fatigue, diarrhea, vomiting, constipation, ALAT elevation, alopecia, infections and arthralgia. Furthermore, ribociclib can induce QT prolongation with a postbaseline QTcF over 480ms occurring in 3.6%-7% of the patients[16, 17, 20]. Adverse events are managed with temporary dose interruptions or dose reductions. Full ribociclib dosage starts at 600mg daily (3 weeks on, 1 week off) with a possibility for lower doses of 400mg or 200mg. Throughout the MONALEESA trials between 31%-54.5% (highest in MONALEESA-2) of patients required at least one dose reduction due to adverse events[16, 17, 20]. Thus, dose adjustments seem an important aspect of ribociclib treatment. However, patients receiving lower dosage could potentially end up with an inferior effect compared to those receiving ribociclib at full dosage. Therefore, while dose reductions are a necessary step to circumvent severe adverse events, lowering dosage of a newly approved drug as ribociclib should be done with caution, as the consequences are not well described.

Furthermore, as results from randomized controlled trials sometimes prove difficult to generalize into a broader patient population, since general clinical settings and patient characteristics may differ from those enrolled in clinical trials[21]. Observational studies based on electronic health records from a real-world clinical setting provide a necessary supplementary source of data to support results from clinical trials. These real-world data offer important information on actual tolerability and efficacy in broader populations[22]. We therefore sought to describe how results on efficacy and tolerability from the MONALEESA trials translate to ER + HER2- MBC patients treated with ribociclib and endocrine therapy in a real-world clinical setting. In addition, we would investigate if dose reductions had any impact on efficacy, an important information when treating patients with ribociclib.

Methods

In this study we present data from a retrospective cohort including patients with ER + HER2- MBC treated at three Danish oncology departments (Aarhus, Copenhagen and Odense). The study population consists of women who initiated treatment with ribociclib and endocrine therapy (aromatase inhibitor or fulvestrant) between 1st January 2018 and 30th March 2020. Patients were followed until data cut-off on

31st July 2020. Patients previously treated with another CDK 4/6 inhibitor (e.g. abemaciclib or palbociclib), had a Child Pugh score ≤ B or concurrent malignancies (excluding T1 melanoma or non-melanoma skin cancer) were excluded from the analyses. Patients were identified using electronic medical records. All data were obtained manually by two investigators and stored in a REDcap database[23, 24]. The primary outcome was tolerability including frequency of dose reduction, and secondary outcome was progression-free survival (PFS). To be able to explore whether dose reduction had any impact on efficacy, patients who received only one cycle or less (≤ 28 days) of ribociclib treatment was identified, but otherwise not included in our analysis.

Patients characteristics, data on dose reduction and frequency of adverse events are presented with descriptive statistics. Results on adverse events were based on data from electronic health records. This data was retrospectively categorized according to the CTCAE by two of the authors [25]. Baseline was defined as day 1 in the first ribociclib cycle. PFS, shown as Kaplan-Meier plots, was defined as time from baseline to progression or death of any cause, whichever came first. Median follow-up time was calculated as Kaplan-Meier estimate of potential follow-up[26]. When appropriate, Kaplan-Meier curves were compared using log-rank test. In our analysis of whether dose reduction had any impact on PFS, the study population was divided into three groups. Firstly, patients without any dose reduction throughout treatment, secondly, patients with first dose reduction occurring within 3 months (early dose reduction) and thirdly, patients with first dose reduction occurring later than 3 months (late dose reduction). This partition was done to minimize immortal time bias, since patients with late dose reductions already had proven as drug responders. As a result, PFS was only compared between patients without dose reduction and those with early dose reduction. Both in the groups with early and late first dose reduction, patients could eventually receive a second dose reduction. For the analysis of PFS, patients were not distinguished whether final dose received was 200mg or 400mg. Finally, to predict factors associated with dose reduction both a univariate and multivariate logistic regression were performed using patients' baseline characteristics. If the p-value > 0.2 in univariate regression, the variable was not considered for multivariate adjustment. Statistical analyses were performed using r (version 4.0.2). Results were considered significant if $p < 0.05$. The project was approved by the institutional review board at Copenhagen University Hospital, Odense University Hospital and Aarhus University Hospital.

Results

Study population

A total of 148 ER+ HER2- MBC patients who initiated ribociclib and endocrine therapy from 3rd January 2018 to 30th March 2020 were identified. From this sample, a group of 20 patients were treated with only one full cycle or less and therefore not included in our analysis. These patients stopped treatment untimely due to early progression or death (n=5), due to patient's wish (n=3), miscellaneous reasons decided by the physician (n=3) or discontinued treatment due to early presenting adverse events including QTcF-prolongation (n=3), elevated alanine aminostranferase (ALAT) (n=2), vomiting (n=1),

neutropenia combined with prebaseline long QT-interval (n=1), diarrhea (n=1) and itchy scalp with facial swelling (n=1). Thus, in total 128 patients were evaluable for our study. Baseline characteristics for both the final study population and the 20 patients with untimely treatment discontinuation are shown in Table 1. **[Table 1 near here]**. In the final study population, the median age was 67 (22-85) years and included both postmenopausal (n=110) and premenopausal women (n=18). Patients received ribociclib co-administrated with either an AI (68.8%) or fulvestrant (31.2%). All premenopausal patients also have ovarian suppression with either an GnRH agonist (83.3%) or bilateral oophorectomy (16.7%). Choice of endocrine therapy depended on patient's history of endocrine treatment, with letrozole being the predominant choice (64.1%). Patients had either primary disseminated breast cancer (26.6%) or recurrent metastatic disease (73.4%). Ribociclib was first-line treatment in most cases (75.0%), while 25.0% of patients had previously received treatment for MBC with either chemotherapy and/or endocrine therapy. Metastatic lesions were most prominent in bones (75.0%) of which 24.6% had bone-only disease at baseline. Visceral metastasis has present in 57.0% of the patients and lymph nodes involvement in 46.9. Ribociclib treatment was mostly initiated in patients with an ECOG performance score of 0 or 1, but nine (7.0%) patients had a performance score of 2.

Tolerability and treatment patterns

At data cut-off on 31st July 2020, 59 patients (46.1%) were still on ribociclib treatment. Data on tolerability are shown in Table 2. **[Table 2 near here]**. The most common reason for treatment discontinuation (excluding progression) was treatment associated toxicity (23.2%). Patients most often either continued endocrine monotherapy (45.5%) or switched to another CDK 4/6 inhibitor (40.9%) if treatment was discontinued for other reasons than progression or death. Dose reduction was an important aspect of ribociclib treatment, with one or more dose reductions occurring in 62 patients (48.4%). Of all dose reductions, 96% were due to adverse events. Two patients started on a reduced dose due to clinician's decision based on general weak health. Dose reductions generally occurred early in the treatment period, with a median time to first dose reduction of 2.2 months (range 0.9-17.3).

Adverse events during ribociclib treatment

Generally, reported adverse events were mild (grade I-II) apart from neutropenia. As noted earlier, results included on adverse events (Table 3) only represents patients with more than one month of ribociclib treatment. **[Table 3 near here]**. Neutropenia was the most frequent adverse event, occurring in 89.8% of patients. Nine (7%) patients experienced grade IV neutropenia and 58 (45.3%) experienced grade III. Besides neutropenia, patients frequently experienced adverse events including fatigue (57.0%), nausea (50.8%), thrombocytopenia (39.8%), cutaneous reaction (35.9%), and increase in alanine-aminotransferase (ALAT) (35.9%). A small proportion of patients (3.1%) developed abnormal ECG-changes during treatment, with three patients (2.3%) having treatment discontinued or dose reduced due to QT-prolongation. Eleven patients were hospitalized with symptoms compatible with an infection. A

larger group of patients (n=33) reported having had symptoms which could indicate an infection. In total, one third (34.4%) of patients experienced signs of infections during the treatment course. Lastly, 17 (13.3%) patients were hospitalized for other reasons than infection. Reasons for hospitalization included general bad health condition with/without electrolyte deficiency due to unknown cause, morbidities following disseminated cancer (e.g. suspicion of metastatic spinal cord compression, venal thrombosis, ileus) and elective procedures as surgery.

Efficacy

Patients were followed for a median follow-up time of 18.4 months. At data cut-off 31st July 2020, progression of metastatic disease or death from any cause had occurred in 58 patients. Figure 1 depicts Kaplan-Meier plots of PFS. **[Figure 1 near here]**. The overall median PFS for included patients was estimated to 19.2 months (CI-95%: 14.3-not reached). In addition, PFS was compared between patients with dose reductions versus patients without any dose reduction during treatment. The median PFS for patients without any dose reduction was 12.2 months (CI-95%: 7.3-not reached), whereas those patients with early first dose reduction had a median PFS of 19.2 months (CI-95%: 14.3-not reached). Log-rank test was done between early dose reduction and no dose reduction with P-value = 0.078. The group with late dose reduction had a median PFS of 22.1 months (CI-95%:22.13-not reached). To investigate if patient characteristics could predict which patients were at risk of dose reduction, logistic regression was performed (Table 4). **[Table 4 near here]**. Older patients were more likely to have their dose reduced, as age was associated with increased odds per year (OR_a = 1.05, CI-95%: 1.02-1.09). In contrast, both the choice of fulvestrant as endocrine drug (OR_a = 0.30, CI-95%: 0.12-0.73) and lymph node involvement at baseline (OR_a = 0.41, CI-95%: 0.18-0.89) were associated with lower odds for having dose reduction. Patients who received ribociclib treatment as second-line or beyond, did not have significant higher odds of requiring dose reduction compared to patients treated in a first-line regime.

Discussion

Here we present data on ER+ HER2- MBC patient treated with ribociclib and endocrine therapy from three Danish departments of oncology. First and foremost, our analyses indicate that patients who receives dose reductions during ribociclib treatment do not have a shorter PFS compared to patients who continue receiving ribociclib in full dosage. Even when adjusting for patients with late dose reduction, there is a tendency (p=0.078) towards better effect in patients that have been dose reduced. This tendency could be due to unknown confounding given the chosen study design or remaining immortal time bias. However our results indicate that dose reduction of ribociclib is safe, and the results fits preliminary results from MONALEESA trials subgroup analysis [27]. Similar results have previously been published concerning the CDK4/6 inhibitor Palbociclib [28]. Still, caution is advised in concluding that ribociclib in lower doses (200-400mg) have equal (or better) efficacy than full dosage (600mg). For this, more real-world experience and research are needed, including randomized clinical trials (e.g. ClinicalTrials.gov #: NCT03822468).

Overall, our study population consisting of both post-/premenopausal women treated with ribociclib and an AI or fulvestrant should represent patients found within all three MONALEESA trials[15–17]. Unlike MONALEESA-2 where all patients were treated in a first-line setting, here 25.0% of patients received ribociclib treatment as second line or beyond. With that in mind, our median PFS of 19.2 months (95%-CI:14.3-not reached) seems slightly lower than the 25.3 months (95%-CI = 23.0-30.3) observed in MONALEESA-2[15], but closer to results from MONALEESA-3. Here the median PFS was 20.5 months (CI-95% = 18.5-23.5) and 22.7% of included patients had received up to one line of endocrine therapy for advanced disease [16]. Findings from both MONALEESA 3 and 7 suggest that patients derive beneficial effect of ribociclib despite previously having received up to one line of endocrine therapy [16] or chemotherapy[17]. However, in other retrospective studies on CDK 4/6 inhibitors, actual median PFS is, unsurprisingly, lowered in patients receiving ribociclib treatment beyond a first-line setting[12, 29].

Another consideration is that, in contrary to the MONALEESA trials, our real-world study population also include a small proportion (7%) of patients with performance score of 2. Poor performance score might negatively impact survival in breast cancer patients[30, 31]. Overall, comparison of PFS from clinical trials to real-world evidence should be done with caution due to differences in clinical settings and potential unknown differences in patient characteristics. However, given our inclusion of patients receiving ribociclib in a second line or beyond and few patients with a performance score of 2, we report an efficacy of ribociclib in ER+ HER2- MBC patients comparable to results from the MONALEESA trials.

We identified a group of 20 patients who only received ribociclib between a few days and just merely completing the single treatment cycle (28 days). We found no specific baseline characteristics associated with this group of patients (Table 1). Underlining the fact that it can be difficult to determine whether patients should initiate ribociclib treatment even when they are formally eligible for the treatment.

In the present study, 46.9% of patients required at least one dose reduction, this seems comparable to results from MONALEESA-2 (57.5%), MONALEESA-3 (37.9%) and MONALEESA-7 (35%). We found lower risk of requiring dose reduction, when the endocrine drug co-administrated with ribociclib was fulvestrant compared to an aromatase inhibitor (OR_a = 0.30, CI-95%: 0.12-0.73). While this difference could be explained by a different safety profile between fulvestrant, generally aromatase inhibitors are thought to have a similar safety profile as fulvestrant[32, 33] and both MONALEESA-2 and 3 report almost same frequency of adverse events[15, 16]. While our regression analysis indicates no association between previous treatment for advanced disease and dose reduction, a combination of the patient's history of both previous (neo)adjuvant treatment and previous lines of endocrine/chemotherapy could be a possible explanation. Moreover, the patients with lymph node involvement at baseline have reduced odds of requiring dose reduction. In the tolerability data, there is no difference between baseline characteristics or adverse events reported in patients with lymph node involvement compared to those without lymph node involvement (data not shown). So, it remains speculative, what causes this difference in risk.

Generally, the commonly reported adverse events in the present study supports a manageable safety profile as evident from the MONALEESA trials[15–17]. Occurrence of neutropenia grade III (45.3%) and IV

(7.0%) in this real-world population, seems comparable to numbers observed across the MONALEESA trials, with grade III occurring between 46.6% to 52.4% and similarly grade IV in 6.8% to 10%. During treatment three (2.3%) patients developed postbaseline QTc prolongation requiring dose reduction or discontinuation. In addition, three patients were non-eligible for ribociclib treatment due to QTc prolongation at ECG control 14 days posttreatment start. Compared to the MONALEESA trials where 3.6-7% developed postbaseline QTc prolongation of >480ms[15–17], our real-world data supports recommendations that physician should monitor ECG throughout a ribociclib treatment course.

Some of the study limitations naturally adhere to the chosen study design. Retrospective studies rely on precise information from electronic health records and lack of randomization means results could be impacted by confounding. Despite inclusion of patients from three different institutions, our moderate sample size (n=128) should be considered before generalizing our results into broader populations. Furthermore, as collection and categorizing of adverse events were done retrospective by the authors, there is a risk of misclassification. This risk is not present concerning neutropenia, thrombocytopenia and ALAT increase, as these adverse events were assessed by blood samples available for all patients (except one).Finally, our PFS analysis of patients receiving ribociclib in reduced dose, does not differentiate if patient's final dose was 400mg or 200mg.

Conclusion

Our results from patients treated in real-world clinical settings indicate that dose reduction of ribociclib is not associated with a loss of efficacy. Furthermore, the results from this study concerning tolerability and efficacy is in line with the results presented in the MONALEESA clinical trials.

Declarations

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest: Disclosure statements: Tobias Berg: Institutional grants from the Danish Cancer Society, Roche, Novartis, Pfizer, AstraZeneca, Eisai and VentureOncology. Anders Bonde Jensen: Received travel grant from Pfizer, AstraZeneca and received honorary for presentations from Pfizer and Daiichi Sankyo. All other authors report no conflict of interests

Availability of data and material: The dataset generated during the current study are not publicly available due to confidentiality (including individual privacy) but are available from the corresponding author on reasonable request.

Code availability: Code used for analysing dataset in r 4.0.2 are available upon reasonable request.

Authors' contributions: All authors contributed to the study conception and design. Tobias Berg, Annette Kodahl and Anders Jensen were responsible for data availability and necessary permits. Data collection

was performed by Kristoffer Kristensen and Ida Marie Nedergaard Thomsen. All authors participated in analysis of data. The first draft of the manuscript was written by Kristoffer Kristensen and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Ethics approval: This study was approved by the institutional board at the Copenhagen University Hospital, Odense University Hospital and Aarhus University Hospital

Consent to participate: Not applicable

Consent to publication: Not applicable

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A J Clin 00:1–31 . https://doi.org/10.3322/caac.21492.
2. Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, Gettins L, Godwin J, Gray R, Liu H, McGale P, MacKinnon E, McHugh T, James S, Morris P, Pan H, Peto R, Read S, Taylor C, Wang Y, Wang Z, Dowsett M, Forbes JF, Ingle J, Coates A, Cuzick J, Gnant M, Aihara T, Bliss J, Boccardo F, Coombes RC, Dubsky P, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, Van De Velde C, Baum M, Buzdar A, Sestak I, Markopoulos C, Fesl C, Jakesz R, Colleoni M, Gelber R, Regan M, Von Minckwitz G, Snowdon C, Goss P, Pritchard K, Anderson S, Costantino J, Mamounas E, Ohashi Y, Watanabe T, Bastiaannet E, Bergh J, Albain K, Arriagada R, Barlow W, Bergsten-Nordström E, Buyse M, Cameron D, Coleman R, Correa C, Davidson N, Di Leo A, Ewertz M, Geyer C, Gianni L, Goldhirsch A, Hayes D, Hill C, Janni W, Martín M, Norton L, Paik S, Perez E, Piccart M, Pierce L, Raina V, Ravdin P, Robertson J, Rutgers E, Sparano J, Swain S, Viale G, Wang X, Whelan T, Wilcken N, Winer E, Wolmark N, Wood W (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352 . https://doi.org/10.1016/S0140-6736(15)61074-1
3. Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW (2018) Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectr 2:1–10 . https://doi.org/10.1093/jncics/pky062
4. Waks AG, Winer EP (2019) Breast Cancer Treatment: A Review. JAMA - J. Am. Med. Assoc. 321:288–300
5. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Dié Ras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen B V., Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP (2018) 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 29:1634–1657 . https://doi.org/10.1093/annonc/mdy192

6. O'Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 13:417–430 . https://doi.org/10.1038/nrclinonc.2016.26
7. Kent LN, Leone G (2019) The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer 19:326–338 . https://doi.org/10.1038/s41568-019-0143-7
8. Finn RS, Aleshin A, Slamon DJ (2016) Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 18:1–11 . https://doi.org/10.1186/s13058-015-0661-5
9. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ (2016) Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 375:1925–1936 . https://doi.org/10.1056/nejmoa1607303
10. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S, Masuda N, Colleoni M, Demichele A, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive , HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): fi nal analysis of the multicentre , double-blind. Lancet Oncol 17:425–439 . https://doi.org/10.1016/S1470-2045(15)00613-0
11. Bui TB V, Burgers DMT, Agterof MJ, Garde EMW Van De (2019) Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced / Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy. 13: . https://doi.org/10.1177/1178223418823238
12. Varella L, Samuel A, Xuefei E, Megan J, Halle K, Thomas G, Jame B, Alberto A (2019) Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res Treat 176:429–434 . https://doi.org/10.1007/s10549-019-05176-1
13. Goetz MP, Toi M, Campone M, Trédan O, Bourayou N, Sohn J, Park IH, Paluch-Shimon S, Huober J, Chen SC, Manso L, Barriga S, Freedman OC, Jaliffe GG, Forrester T, Frenzel M, Smith IC, Di Leo A (2017) MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638–3646 . https://doi.org/10.1200/JCO.2017.75.6155
14. Carter GC, Sheffield KM, Gossai A, Huang Y-J, Zhu YE, Bowman L, Smith EN, Mathur R, Cohen AB, Baxi S, Rybowski S, Chong AL, Seidman AD (2020) Abstract P2-08-12: Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2- metastatic breast cancer. Cancer Res 80:P2-08-12 LP-P2-08–12 . https://doi.org/10.1158/1538-7445.SABCS19-P2-08-12
15. Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke E-M, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng L-M, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 375:1738–1748 . https://doi.org/10.1056/nejmoa1609709
16. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Val Bianchi G, Esteva FJ, Martín M, Nusch A, Sonke GS, De La Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Lorenc KR,

Miller M, Taran T, Jerusalem G (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465–2472 . https://doi.org/10.1200/JCO.2018.78.9909

17. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19:904–915 . https://doi.org/10.1016/S1470-2045(18)30292-4
18. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi G V., Esteva FJ, Martín M, Nusch A, Sonke GS, De La Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382:514–524 . https://doi.org/10.1056/NEJMoa1911149
19. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:307–316 . https://doi.org/10.1056/NEJMoa1903765
20. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541–1547 . https://doi.org/10.1093/annonc/mdy155
21. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM (2016) Real-World Evidence — What Is It and What Can It Tell Us? N Engl J Med 375:2293–2297 . https://doi.org/10.1056/nejmsb1609216
22. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS (2018) Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv. Ther. 35:1763–1774
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf 42:377–381 . https://doi.org/10.1016/j.jbi.2008.08.010.Research
24. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, Neal LO, Mcleod L, Delacqua G, Delacqua F, Duda SN, Consortium R (2019) The REDCap Consortium: Building an International Community of Software Platform Partners. J Biomed Inform 1–24 . https://doi.org/10.1016/j.jbi.2019.103208.The

25. National Cancer Institute (1999) Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. Cancer Ther Eval Progr 183
26. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343–346 . https://doi.org/10.1016/0197-2456(96)00075-X
27. Beck JT, Neven P, Sohn J, Chan A, Sonke GS, Bachelot T, Campos-Gomez S, Martin M, Bardia A, Alam J, Miller M, Diaz-Padilla I, Kong O, Hart L (2019) Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials. Cancer Res 79:P6-18-06 LP-P6-18–06 . https://doi.org/10.1158/1538-7445.SABCS18-P6-18-06
28. Wilkie J, Schickli MA, Berger MJ, Lustberg M, Reinbolt R, Noonan A, Ramaswamy B, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Stover DG, Li J, Vargo CA (2020) Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. Clin Breast Cancer 20:33–40 . https://doi.org/10.1016/j.clbc.2019.06.010
29. Fountzilas E, Koliou GA, Vozikis A, Rapti V, Nikolakopoulos A, Boutis A, Christopoulou A, Kontogiorgos I, Karageorgopoulou S, Lalla E, Tryfonopoulos D, Boukovinas I, Rapti C, Nikolaidi A, Karteri S, Moirogiorgou E, Binas I, Mauri D, Aravantinos G, Zagouri F, Saridaki Z, Psyrri A, Bafaloukos D, Koumarianou A, Res E, Linardou H, Mountzios G, Razis E, Fountzilas G, Koumakis G (2020) Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: The experience of the Hellenic Cooperative Oncology Gr. ESMO Open 5:1–9 . https://doi.org/10.1136/esmoopen-2020-000774
30. Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, Cortes J (2014) A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. Breast 23:656–662 . https://doi.org/10.1016/j.breast.2014.06.017
31. Ryberg M, Nielsen D, Østerlind K, Skovsgaard T, Dombernowsky P (2001) Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 12:81–87 . https://doi.org/10.1023/A:1008384019411
32. Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388:2997–3005 . https://doi.org/10.1016/S0140-6736(16)32389-3
33. Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J (2017) Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: Final results of the randomized phase III femara versus anastrozole clinical evaluation . J Clin Oncol 35:1041–1048 . https://doi.org/10.1200/JCO.2016.69.2871

Tables

Table 1: Baseline characteristics

Table 1: Overview of patient characteristics at baseline. All patients from the total study population included. *defined at either age over 60 years, absent menstruation more than 12 months or bilateral oophorectomy prior to ribociclib treatment. †Disease free interval defined as date from last intentional curative surgery to disease relapse. Disease free interval only listed for patients receiving ribociclib in a first-line setting. In some cases, total sum not equal 100% due to rounding.

	Included patients N = 128	Non-evaluable patients N = 20
	N (%)	N (%)
Age, median [range] -years	67 [22-85]	69.00 [45-81]
Menopausal status		
Postmenopausal*	110 (85.9)	18 (90.0)
Premenopausal	18 (14.1)	2 (10.0)
For premenopausal, method for ovarian suppression		
GnRH-agonist	15 (83.3)	2 (100.0)
Bilateral oophorectomy	3 (16.7)	0 (0.0)
Choice of endocrine drug		
Fulvestrant	40 (31.2)	9 (45.0)
Aromatase inhibitor	88 (68.8)	11 (55.0)
Letrozole	82 (93.2)	9 (81.8)
Exemestane	5 (5.7)	2 (18.2)
Anastrozole	1 (1.1)	0 (0.0)
Recurrent or primary metastatic disease		
De novo	36 (28.1)	2 (10.0)
Recurrence	92 (71.9)	18 (90.0)
For recurrent disease, disease free interval†		
Less than or 12 months	5 (7.7)	0 (0.0)
More than 12 months	60 (92.3)	12 (100.0)
Previously treated, chemotherapy		
(Neo)adjuvant	41 (32.0)	7 (35.0)
Advanced	17 (13.3)	3 (15.0)
Previously treated, endocrine therapy		
(Neo)adjuvant	77 (60.2)	16 (80.0)
Advanced	25 (19.5)	5 (25.0)
Sites of lesions		

Bones	96 (75.0)	13 (65.0)
Bone only	31 (24.6)	6 (30.0)
Lymph nodes	60 (46.9)	8 (40.0)
Visceral	73 (57.0)	11 (55.0)
Lung	34 (26.6)	8 (40.0)
Liver	40 (31.2)	3 (15.0)
Other visceral organs	20 (15.6)	4 (20.0)
Brain	7 (5.5)	1 (5.0)
Other (e.g. breast, skin)	14 (10.9)	1 (5.0)
ECOG performance score		
0	67 (52.3)	6 (30.0)
1	42 (32.8)	8 (40.0)
2	9 (7.0)	4 (20.0)
Missing	10 (7.8)	2 (10.0)

Table 2: Tolerability and dose reductions

Table 2: Overview of patient stopping treatment, and dose modification occurring during treatment. Unless otherwise specified value shown denotes number of patients (percentage).

Reason for treatment stop before data cut-off	
# of patients	n = 69
Progression	43 (62.3)
Toxicity*	16 (23.2)
Patient's wish	4 (5.8)
Death following hospitalization	4 (5.8)
Other	2 (2.9)
Post-discontinuation therapy for patients stopping ribociclib treatment due to toxicity, patient's wish or other reasons	
# of patients	n = 22
Only endocrine therapy	10 (45.5)
Chemotherapy	2 (9.1)
Other CDK 4/6 inhibitor	9 (40.9)
Treatment stopped	1 (4.5)
Dose reductions during treatment	
	n = 128
Patients starting treatment at reduced dose	2 (1.7)
at 400mg	1 (0.8)
at 200 mg	1 (0.8)
Patients with dose reduction during treatment	60 (46.9)
months to first reduction, median[range]	2.2 [0.9-17.3]
First dose reduction within 3 months	40 (66.6)
First dose reduction 600mg to 400mg	59(98.3)
First dose reduction 600mg to 200mg	1 (1.7)
Of these, patients with 2 dose reductions	17(13.3)
months to second reduction, median [range]	6.5 [1.8-17.5]

*Treatment discontinuation due to toxicity was ultimately decided by treating clinician.

Table 3: Adverse events among the patients. N = 128

Table 3: Adverse events reported during ribociclib treatment. Most graded using CTCAE 5. *including symptoms from nose, eye and genitals.

Graded adverse events			
	Any grade	***Grade III***	***Grade IV***
	number of patients (%)		
Any adverse event	128 (100)	63 (49.2)	10 (7.8)
Neutropenia	115 (89.8)	58 (45.3)	9 (7)
Fatigue	73 (57.0)	2 (1.6)	0 (0)
Nausea	65 (50.8)	0 (0)	0 (0)
Thrombocytopenia	51 (39.8)	1 (0.8)	1 (0.8)
Cutaneous reaction	46 (35.9)	1 (0.8)	0 (0)
ALAT increase	46 (35.9)	5 (3.9)	0 (0)
Constipation	36 (28.1)	0 (0)	0 (0)
Muscle-joint pain	32 (25.0)	2 (1.6)	0 (0)
Diarrhea	28 (21.9)	1 (0.8)	0 (0)
Mucosal dryness*	26 (20.3)	0 (0)	0 (0)
Hot flush	24 (18.8)	0 (0)	0 (0)
Vomiting	23 (18.0)	0 (0)	0 (0)
Alopecia	17 (13.3)	0 (0)	0 (0)
Oral Mucositis	15 (11.7)	1 (0.8)	0 (0)
Dysethesia	14 (10.9)	0 (0)	0 (0)
Dyspepsia/stomach pain	9 (7.0)	0 (0)	0 (0)
Dyspnoe	6 (4.7)	1 (0.8)	0 (0)
Coughing	5 (3.9)	0 (0)	0 (0)
Dizziness	4 (3.1)	0 (0)	0 (0)
Dysgeusia	3 (2.3)	0 (0)	0 (0)
Other adverse events	11 (8.6)	0 (0)	0 (0)
Non-graded adverse events			
Patients with abnormal ECG-changes leading to treatment discontinuation or reduction			4 (3.1)
	QT_cF-prolongation		3 (2.3)
	Inverted T-waves		1 (0.8)

Patients with reported infection during treatment		44 (34.4)
	Hospitalized	11 (8.6)
	Self-reported	33(25.8)
Patients hospitalized for other reasons than infection		17 (13.3)
	General health condition	6 (4.6)
	Attributable to disseminated cancer	6 (4.6)
	Elective procedures	4 (3.1)
	Other	1 (0.8)

Table 4: Factors predicting dose reduction. N = 128

Characteristics	**Univariate**			**Multivariate**		
	OR	95-% CI	p-value	OR_a	95-% CI	p-value
Age	1.04	1.01-1.07	0.013*	1.05	1.02-1.09	0.005**
Chemotherapy†	0.71	0.24-1.99	0.52	-	-	-
Endocrine therapy†	0.65	0.26-1.57	0.35	-	-	-
Recurrent (reference) vs de novo	1.77	0.80-3.98	0.16	1.51	0.60-3.88	0.39
Lymph node involvement	0.46	0.23-0.93	0.033*	0.41	0.18-0.89	0.026*
Bone involvement	0.92	0.41-2.06	0.84	-	-	-
Visceral disease	1.09	0.54-2.19	0.82	-	-	-
Endocrine drug, fulvestrant‡	0.38	0.17-0.83	0.016*	0.30	0.12-0.73	0.01**

Table 4: Univariate and multivariate logistics regression for patient characteristics at baseline predicting any dose reductions during treatment. OR = Odds Ratio unadjusted (univariate). OR_a = Odds Ratio adjusted(multivariate). †Previously treated for advanced disease. ‡ Choice of endocrine drug (fulvestrant or aromatase inhibitor) co-administrated with ribociclib, reference = fulvestrant.

Figures



Figure 1

Progression free survival Kaplan-Meier plots of progression-free survival. a) PFS in total included study population (n=128, events = 58). b) PFS between patients with no dose reduction compared to those with either early or late first dose reduction. Early = before 3 months, late = after 3 months of treatment.